Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

× No keyword cloud information.

74 in total

1. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.

Authors: Gilles Freyer; Ewa Kalinka-Warzocha; Konstantinos Syrigos; Mihai Marinca; Giuseppe Tonini; Say Liang Ng; Zee Wan Wong; Antonio Salar; Guenther Steger; Mahmoud Abdelsalam; Lucy DeCosta; Zsolt Szabo
Journal: Med Oncol Date: 2015-08-28 Impact factor: 3.064

2. Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy.

Authors: Abolfazl Razzaghdoust; Bahram Mofid; Maryam Moghadam
Journal: Support Care Cancer Date: 2018-05-07 Impact factor: 3.603

3. Neutropenic sepsis: management and complications.

Authors: Rachel T Clarke; Tom Jenyon; Victoria van Hamel Parsons; Andrew J King
Journal: Clin Med (Lond) Date: 2013-04 Impact factor: 2.659

4. Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia.

Authors: Leszek Kraj; Joanna Krawczyk-Lipiec; Joanna Górniewska; Grzegorz Orlik
Journal: Biomed Rep Date: 2017-07-04

5. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

Authors: Ida Netterberg; Mats O Karlsson; Elisabet I Nielsen; Angelica L Quartino; Henrik Lindman; Lena E Friberg
Journal: Br J Clin Pharmacol Date: 2018-01-18 Impact factor: 4.335

Review 6. Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.

Authors: Edgar Petru; Christian F Singer; Stephan Polterauer; Arik Galid; Christian Schauer; Johann Klocker; Michael Seifert; Alexander Reinthaller; Christoph Benedicic; Michael Hubalek; Lukas Hefler; Christian Marth; Tonja Scholl-Firon; Gerhard Bogner; Alain-Gustave Zeimet
Journal: Wien Med Wochenschr Date: 2015-10-15

Review 7. Innate immune regulation by STAT-mediated transcriptional mechanisms.

Authors: Haiyan S Li; Stephanie S Watowich
Journal: Immunol Rev Date: 2014-09 Impact factor: 12.988

8. Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis.

Authors: Yuko Kanbayashi; Takeshi Ishikawa; Motohiro Kanazawa; Yuki Nakajima; Rumi Kawano; Yusuke Tabuchi; Tomoko Yoshioka; Norihiko Ihara; Toyoshi Hosokawa; Koichi Takayama; Keisuke Shikata; Tetsuya Taguchi
Journal: Med Oncol Date: 2018-03-16 Impact factor: 3.064

9. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.

Authors: Wendy J Langeberg; Conchitina C Siozon; John H Page; P K Morrow; Victoria M Chia
Journal: Support Care Cancer Date: 2014-03-21 Impact factor: 3.603

Review 10. Supportive Care in Older Adults with Cancer: Across the Continuum.

Authors: Thuy Koll; Mackenzi Pergolotti; Holly M Holmes; Huibrie C Pieters; G J van Londen; Zachary A Marcum; Amy R MacKenzie; Christopher B Steer
Journal: Curr Oncol Rep Date: 2016-08 Impact factor: 5.075